|
May 13
|
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
|
|
May 13
|
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
|
|
May 13
|
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
|
|
May 9
|
Fulcrum Therapeutics to Participate in Upcoming May Conferences
|
|
May 8
|
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
|
|
May 6
|
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
|
|
Mar 28
|
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
|
|
Mar 18
|
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
|
|
Mar 7
|
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
|
|
Mar 5
|
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
|
|
Feb 28
|
Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations
|
|
Feb 28
|
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
|
|
Feb 28
|
Q4 2023 Fulcrum Therapeutics Inc Earnings Call
|
|
Feb 27
|
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023
|
|
Feb 27
|
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
|
|
Feb 11
|
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after 31% loss over the past year
|
|
Dec 7
|
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 9
|
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
|
|
Nov 8
|
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript
|